Today two countries on opposite sides of the world took radically different stances on pharma patents that will have a big impact on the future of drug R&D.
And in a preview of its R&D showcase, the pharma giant--which spent an industry-leading $9.58 billion on R&D last year--offered a bullish assessment of a slate of experimental therapies it believes can break past the $1 billion annual revenue mark.
As Ariad, Pfizer and others make strides with their rival antileukemia compounds, Novartis aims to show how its newer therapy Tasigna helps more patients beat their cancer and stop taking the drug than Gleevec does.
A pair of Novartis ($NVS) leukemia drugs effectively attacked the highly lethal Ebola virus in lab tests, providing clues about what it might take to finally march forward with a treatment against the killer bug.
Shares of Paris-based AB Science shot up yesterday after the drug developer reported strong efficacy results from a midstage study of its experimental drug for gastrointestinal tumors. The treatment,